Status and phase
Conditions
Treatments
About
This is a multicenter, randomized, open label study with blinded outcome assessment to evaluate the impact of additional/intensive LDL-cholesterol reduction with evolocumab on carotid artery atherosclerotic plaques in higher risk subjects with severe asymptomatic but vulnerable plaques.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Additional Inclusion Criteria
If all eligibility criteria listed above are met, participants with only one high risk feature will undergo a time-of-flight MR angiogram, where one additional inclusion criteria will be assessed to confirm eligibility:
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Loading...
Central trial contact
Nicole Cooke
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal